AstraZeneca Korea surpassed 600 billion won in sales last year by supplying the COVID-19 vaccine. According to an audit report by AstraZeneca Korea, the company recorded 655.3 billion won in sales last year. The figure is up 31.6 percent from the previous year's 498.1 billion won.

Operating profit was 26 billion won, up 7.5% from 24.2 billion won a year earlier. It is analyzed that the increase in operating profit was relatively small because there was little difference between the purchase amount and domestic sales amount purchased globally.

AstraZeneca Korea, which has improved its performance with anticancer drug Tagrisso, saw its performance jump significantly last year when it suppli